M.P.H., University of Washington, Epidemiology, 2002.
M.D., Cornell University, Medicine, 1997.
Dr. Casper divides his time between engaging in research, teaching and clinical care. His research efforts focus on the transmission, acquisition, natural history, pathophysiology and treatment of infection-associated cancers with a special focus on human herpesvirus 8 (HHV-8). His immunology work described the first comprehensively-validated serologic assay for detection of antibodies to HHV-8, the original description of neutralizing antibodies to HHV-8 and their role in development of Kaposi Sarcoma (KS), and the characterization of gamma-delta T-cell activity in persons with chronic HHV-infection. He then made the first descriptions of the symptoms and viral replication patterns of HHV-8-infected persons without KS. As part of this work, he studied HHV-8 transmission among couples discordant for HHV-8 infection, and also collaborated with researchers in HIV prevention studies to describe epidemiologic risk factors for acquiring HHV-8 in many different cohorts.
As part of his research into HHV-8, Dr. Casper described the successful use of antiviral therapy for the treatment of multicentric Castleman disease (MCD) and followed this by the first randomized trial of an antiviral against HHV-8. He also utilized information from a large primary HIV clinic to show that the majority of patients with KS in the highly active antiretroviral therapy era have persistent disease, despite the receipt of highly active antiretroviral therapy (HAART) and chemotherapy. This work has informed current and future studies evaluating the role of antiviral drugs in the treatment and prevention of infection-associated cancers.
In 2004, Dr. Casper initiated collaboration with physician-scientists at the Uganda Cancer Institute (UCI) and the Kampala Cancer Registry resulting in the formation of the UCI/Hutchinson Center Cancer Alliance. As Director of this program, based at the Fred Hutchinson Cancer Research Center, he established a translational clinical research site in Kampala. This site currently has 23 ongoing studies examining the control of HHV-8 replication, biomarkers for the prediction of KS development and successful treatment, the immunogenetics of infection-associated cancers, treatment of KS and Burkitt lymphoma, the role of nutrition in the development and treatment of infection-related cancers, and the discovery of novel pathogens associated with cancer. Under Dr. Casper's direction, research is being bolstered with the addition of a new cancer clinic and hospital, a quickly expanding training program, and a state-of-the-art molecular diagnostics laboratory.
American Practioners for Infection Control
Centers for Disease Control
Infectious Diseases Society of America
National Comprehensive Cancer Network
Honors and Awards
2007, Young Investigator Award, School of Medicine, University of Washington
2005, Clinical Scientist Development Award, Doris Duke Charitable Foundation
2001-2003, Special Citation for Fellows-in-Training, Infectious Diseases Society of America
2011, Top Doctor, Seattle Metropolitan Magazine, Fred Hutchinson Cancer Research Center
2005, Distinguished Investigator Award, Spanish Association of Rare Diseases/Castleman Disease
2002, Joel Meyers Infectious Diseases Scholarship Award, Fred Hutchinson Cancer Reserch Center
2005, Stephen L. Sacks Investigator Award, American Herpes Foundation
2007-2009, Assistant Professor, University of Washington, School of Public Health and Community Medicine, Epidemiology
2006, Lecturer, University of Washington, Conjoint 553: Clinical Management of HIV and STIs
2005-2010, Assistant Member, Fred Hutchinson Cancer Research Center, Clinical Research and Public Health Sciences Divisions, Vaccine and Infectious Disease Institute
2005-2009, Assistant Professor, University of Washington, School of Medicine, Medicine, Infectious Disease
2003, Subsitute Faculty, University of Washington, Introduction to Clinical Medicine
2002, Section Leader, University of Washington, School of Medicine, Human Biology 530: Epidemiology and Evidence-based Medicine
Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention.. Current opinion in oncology. 25(5):495-502.. 2013.
Population-based assessment of kaposi sarcoma-associated herpesvirus DNA in plasma among Ugandans.. Journal of medical virology. 85(9):1602-10.. 2013.
A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease.. Clinical cancer research : an official journal of the American Association for Cancer Research.. 2013.
Clinical and Virologic Manifestations of Primary Epstein-Barr Virus (EBV) Infection in Kenyan Infants Born to HIV-Infected Women.. The Journal of infectious diseases.. 2013.
Cutaneous T-cell lymphoma in sub-Saharan Africa.. Journal of the National Comprehensive Cancer Network : JNCCN. 11(3):275-80.. 2013.
An artesunate-containing antimalarial treatment regimen did not suppress cytomegalovirus viremia.. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.. 2013.
Contribution of HIV infection to mortality among cancer patients in Uganda.. AIDS (London, England).. 2013.
Treatment of cancer in sub-Saharan Africa.. The lancet oncology. 14(4):e158-67.. 2013.
Prevention and treatment of cancer-related infections.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(11):1412-45.. 2012.
Meeting the challenge of hematologic malignancies in sub-Saharan Africa.. Blood. 119(22):5078-5087.. 2012.
Reply to letang et Al.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 55(1):158-9.. 2012.
Paradoxical Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients Treated With Combination Antiretroviral Therapy After AIDS-Defining Opportunistic Infection.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 54(3):424-433.. 2012.
Epidemiology, Diagnosis, and Treatment of HIV-Associated Non-Hodgkin Lymphoma in Resource-Limited Settings.. Advances in hematology. 2012:932658.. 2012.
Treatment with valacyclovir, famciclovir, or antiretrovirals reduces human herpesvirus-8 replication in HIV-1 seropositive men.. Journal of medical virology. 83(10):1696-703.. 2011.
Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy.. AIDS (London, England). 25(5):691-700.. 2011.
The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro.. Antimicrobial agents and chemotherapy. 55(6):2696-703.. 2011.
Persistent genital herpes simplex virus-2 shedding years following the first clinical episode.. The Journal of infectious diseases. 203(2):180-7.. 2011.
The increasing burden of HIV-associated malignancies in resource-limited regions.. Annual review of medicine. 62:157-70.. 2011.
Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment.. Current opinion in infectious diseases. 24(4):295-301.. 2011.
Predictors of survival after a diagnosis of non-Hodgkin lymphoma in a resource-limited setting: a retrospective study on the impact of HIV infection and its treatment.. Journal of acquired immune deficiency syndromes (1999). 56(4):312-9.. 2011.
Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children.. Pediatric blood & cancer. 54(5):670-4.. 2010.
How I treat influenza in patients with hematologic malignancies.. Blood. 115(7):1331-42.. 2010.
Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(23):3701-8.. 2010.